New drug trial targets uncontrollable hunger in rare genetic disorder
NCT ID NCT07348601
Summary
This early-stage study is testing an investigational drug called CSTI-500 in people with Prader-Willi syndrome, a rare genetic disorder that causes constant hunger and behavioral challenges. The main goals are to check if the drug is safe and to find the right dose for each person by measuring drug levels in their blood. Researchers will also track changes in symptoms like excessive eating and behavioral issues over 12 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRADER-WILLI SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.